Hib conjugate vaccine(Bharat Biotech International Ltd.)(Hib conjugate vaccine(Bharat Biotech International Ltd.))

概要

基本信息

药物类型

预防性疫苗、结合疫苗

别名

BioHib、Hib conjugate vaccine、Hib vaccine

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染

在研适应症

嗜血杆菌感染

非在研适应症-

原研机构

Bharat Biotech International Ltd.

在研机构

Bharat Biotech International Ltd.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

印度 (2016-02-19),

嗜血杆菌感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的临床试验

JPRN-jRCT1031230708

/ RecruitingN/AIIT

Interchangeability study of switching from DPT-IPV quadrivalent vaccine and Hib vaccine to DPT-IPV-Hib pentavalent vaccine

开始日期2024-05-08

申办/合作机构-

JPRN-jRCTs071230050

/ RecruitingN/AIIT

Specified clinical research to confirm interchangeability between 5-combined vaccine and 4-combined vaccine + Hib vaccine

开始日期2023-08-09

申办/合作机构-

100 项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的专利（医药）

登录后查看更多信息

650

项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的文献（医药）

2025-02-01·Journal of Infection

The need for inclusion of the Hib vaccine in mainland national immunization program in China

Letter

作者: Yin, Jun ; Hu, Huili ; Yu, Dingle ; Yang, Yonghong ; Shen, Xuzhuang ; Wang, Yajuan ; Leng, Zhiqin

2024-12-01·The Lancet Regional Health - Southeast Asia

Routine immunization against Streptococcus pneumoniae and Haemophilus influenzae type B and antibiotic consumption in India: a dynamic modeling analysis

Article

作者: Kumar, Chirag K ; Nandi, Arindam ; Laxminarayan, Ramanan ; Gleason, Alec C. ; Parameswaran, Giridara Gopal ; Kumar, Chirag K. ; Summan, Amit ; Klein, Eili ; Gleason, Alec C

BackgroundChildhood vaccinations can reduce disease burden and associated antibiotic use, in turn reducing the risk of antimicrobial resistance (AMR). We retrospectively estimated the population-level reductions in antibiotic use in India following the introduction of vaccines against Streptococcus pneumoniae and Haemophilius influenzae type B in the national immunization program for children in the mid-2010s and projected future gains to 2028 if vaccination coverage were to be increased.MethodsUsing IndiaSim, a dynamic agent-based microsimulation model (ABM) for India, we simulated the spread of Streptococcus pneumoniae and Haemophilius influenzae type B (Hib) among children to estimate reductions in antibiotic use under the scenarios of: (i) pneumococcal and Hib vaccine coverage levels equivalent to the national coverage of pentavalent diphtheria-pertussis-tetanus third dose (DPT3) compared to a baseline of no vaccination, and (ii) near-universal (90%) coverage of the vaccines compared to pre-COVID national DPT3-level coverage. Model parameters, including national DPT3 coverage rates, were based on data from the National Family Household Survey 2015-2016 and other published sources. We quantified reductions in antibiotic consumption nationally and by state and wealth quintiles.FindingsWe estimate that coverage of S. pneumoniae and Hib vaccines at the same level as DPT3 in India would translate to a 61.4% [95% UI: 43.8-69.5] reduction in attributable antibiotic use compared to a baseline of zero vaccination coverage. Increases in childhood vaccination coverage between 2004 and 2016 have likely reduced attributable antibiotic demand by as much as 93.4% among the poorest quintile. Increasing vaccination coverage by an additional 11 percentage points from 2016 levels results in mortality and antibiotic use across wealth quintiles becoming increasingly similar (p < 0.05), reducing in health inquities. We project that near-universal vaccine coverage would further reduce inequities in antibiotic demand and may eliminate of outbreak-associated antibiotic use from S. pneumoniae and Hib.InterpretationThough vaccination has a complex relationship with antibiotic use because both are modulated by socioeconomic factors, increasing vaccinations for S. pneumoniae and Hib may have a significant impact on reducing antibiotic use and improving health outcomes among the poorest individuals.FundingThe Bill & Melinda Gates Foundation (grant numbers OPP1158136 and OPP1190803).

2024-11-01·International Journal of Risk & Safety in Medicine

Adverse outcome detection of childhood administered thimerosal-free HibTITER^®

Article

作者: Jablonowski, Karl ; Hooker, Brian

Background Haemophilus influenzae type b (HIB) is a gram-negative pathogenic bacterium that mostly impacts the pediatric and geriatric population, sometimes resulting in permanent sequelae or death. Objective In this study we set out to discover adverse outcomes from the thimerosal-free HibTITER® vaccine derived from a Florida Medicaid dataset spanning from January 2003 to June 2007 ( n = 277,484). Methods HIB vaccinated children were isolated from the Florida Medicaid dataset. Using other HIB vaccines as the control, we analyzed diagnoses for statistically significant adverse outcomes related to the HibTITER® vaccine (only the strictest p-value of <0.0001 was used in analyzing this dataset). We simultaneously and independently examined the statistical significance of symptoms reported to VAERS related to HIB vaccines to corroborate our findings ( p-value significance was reported at <0.05, <0.001, and <0.0001). Results The study revealed 19 individual ICD-9 codes positively associated ( p-value<0.0001 post Bonferroni correction) with recipients of the HibTITER® vaccine within 30-days of vaccination. Of these conditions, 14 have VAERS corroborators. The diseases span severity from mild to life-threatening and areas of respiration (e.g., asthma), gastrointestinal, otolaryngologic (e.g., common cold), dermatologic, generalized infections (e.g., tuberculosis), and other conditions. Conclusion Incidence of 19 different medical conditions was significantly higher compared to the control group who received other HIB vaccine formulations. These results were corroborated using the VAERS database, and have profound medical implications for the estimated 35 million Americans between the ages of 16 and 33 who received the vaccine.

100 项与 Hib conjugate vaccine(Bharat Biotech International Ltd.) 相关的药物交易

登录后查看更多信息